SEC Form 4 · accession 0001144204-19-000788
Cyclacel Pharmaceuticals, Inc. · CYCC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Spiro George Rombotis
Officer — President and CEO · Director
Period of report
Jan 3, 2019
Accepted (ET)
Jan 7, 2019 · 9:26 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001130166
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| OptionF2,F1 | $0.71 | Jan 4, 2019 | A | 508,198 | A | — | Jan 4, 2029 | Common Stock | 508,198 | 508,198 | D |
| OptionF3 | $1.74 | Jan 3, 2019 | A | 15,625 | A | — | Dec 29, 2027 | Common Stock | 15,625 | 15,625 | D |
| OptionF4 | $1.56 | Jan 3, 2019 | A | 14,375 | A | — | Feb 22, 2028 | Common Stock | 14,375 | 14,375 | D |
Explanation of responses
- F1These securities are exercisable over a three-year period, with 1/36 of the options granted vesting on a monthly basis.
- F2These securities were granted as part of the Issuer's annual compensation review to executive officers.
- F3On December 29, 2017, Spiro Rombotis was granted an option to purchase certain shares of common stock, which option shall vest according to the satisfaction of performance criteria. Certain performance criteria were confirmed to have been met on January 3, 2019, resulting in the vesting of the option as to 15,625 shares.
- F4On February 22, 2018, Spiro Rombotis was granted an option to purchase certain shares of common stock, which option shall vest according to the satisfaction of performance criteria. Certain performance criteria were confirmed to have been met on January 3, 2019, resulting in the vesting of the option as to 14,375 shares.